Educational dose math only — not medical advice, not a product recommendation, and not a pass/fail on whether a supplement will work for you.
0 100% 150%+

—

Enter label dose

Trial reference

From your label

Per-day total — not per serving unless you take one serving

Enter your label dose — the gauge updates instantly.

Multicentre double-blind RCT (51 arginine / 47 placebo) in vasculogenic ED. IIEF-6 and cavernous peak systolic velocity both improved, but only 24% reached scores compatible with no ED — mostly the mild-ED subgroup. High daily gram burden vs citrulline trials.

Educational only — not medical advice. Disclaimer.

Want the outcome before the arithmetic? The reason check opens any registry entry on this page with its trial result first, then compares your daily intake with the studied amount.

NIH DSLD market slice

Median0.8 g
Products3,121
Below99%

Bulk CSV dump 16 January 2026 · label entries through 2025. Disclosed amounts only — proprietary blends without gram weights excluded.

Trial floors

Primary

Menafra 2022 (vasculogenic ED) · 6 g over 3 months (medium evidence · how we grade this) · Benefit shown — Multicentre double-blind RCT (51 arginine / 47 placebo) in vasculogenic ED. IIEF-6 and cavernous peak systolic velocity both improved, but only 24% reached scores compatible with no ED — mostly the mild-ED subgroup. High daily gram burden vs citrulline trials.

Safety red flags

  • On nitrates: cardiologist decision first; treat lightheadedness, meaning dizziness from a blood-pressure drop, as a signal to stop and call.
  • With PDE5 inhibitors: prescriber approval first, with blood pressure monitoring.

Label reading notes

  • Six grams per day is a large capsule/powder load — check serving count on the label.
  • Low-dose "NO booster" arginine (1–2 g/day) sits far below the vasculogenic ED trial dose and will not match that evidence on the label.
  • Do not stack with PDE5 inhibitors or nitrates without clinician sign-off. GI side effects are common at effective gram doses.